SBRT Does Not Improve Efficacy of Nivo-Ipi in Advanced Merkel Cell Carcinoma
SBRT did not improve the efficacy of nivolumab-ipilimumab in patients with advanced Merkel cell carcinoma in a phase 2 study.
SBRT did not improve the efficacy of nivolumab-ipilimumab in patients with advanced Merkel cell carcinoma in a phase 2 study.
Risk of stage-specific Merkel cell carcinoma (MCC) recurrence and mortality over time since diagnosis is estimated.